Insight into the effect of phosphorus poisoning of Cu/zeolites with different framework towards NH3-SCR

Cu/zeolites were prepared to elucidate the effect of phosphorus poisoning on different zeolite framework structures for NH3-SCR. The results show that there are significant differences in phosphorus poisoning depending on the zeolite framework structure. The PO3−/PO43− species gradually decreased along with an increase in P2O5 in the following order: Cu/SSZ-13, Cu/ZSM-5, and Cu/BEA. One possible reason could be the increased pore size of these zeolites, which results in less steric hindrance for larger P2O5 species. P2O5 is suggested to enhance the redox ability of Cu ions, which results in an increase in low-temperature activity in NH3-SCR, whereas Cu ions were significantly poisoned by PO3−/PO43−, resulting in low-temperature deactivation. Furthermore, the effect of phosphorus poisoning on the structure of Cu/ZSM-5 was found to be much greater than that of Cu/BEA and Cu/SSZ-13, possibly due to phosphorus attacked the surface defects of the zeolite, causing local expansion and cracking

UFMylation of MRE11 is essential for telomere length maintenance and hematopoietic stem cell survival

International audienc

Wound Healing after Acellular Dermal Substitute Positioning in Dermato-Oncological Surgery: A Prospective Comparative Study

Background: MatriDerm and Integra are both widely used collagenic acellular dermal matrices (ADMs) in the surgical setting, with similar characteristics in terms of healing time and clinical indication. The aim of the present study is to compare the two ADMs in terms of clinical and histological results in the setting of dermato-oncological surgery. Methods: Ten consecutive patients with medical indications to undergo surgical excision of skin cancers were treated with a 2-step procedure at our Dermatologic Surgery Unit. Immediately after tumor removal, both ADMs were positioned on the wound bed, one adjacent to the other. Closure through split-thickness skin grafting was performed after approximately 3 weeks. Conventional histology, immunostaining and ELISA assay were performed on cutaneous samples at different timepoints. Results: No significant differences were detected in terms of either final clinical outcomes or in extracellular matrix content of the neoformed dermis. However, Matriderm was observed to induce scar retraction more frequently. In contrast, Integra was shown to carry higher infectious risk and to be more slowly reabsorbed into the wound bed. Sometimes foreign body-like granulomatous reactions were also observed, especially in Integra samples. Conclusions: Even in the presence of subtle differences between the ADMs, comparable global outcomes were demonstrated after dermato-oncological surgery

Wound Healing after Acellular Dermal Substitute Positioning in Dermato-Oncological Surgery: A Prospective Comparative Study

Background: MatriDerm and Integra are both widely used collagenic acellular dermal matrices (ADMs) in the surgical setting, with similar characteristics in terms of healing time and clinical indication. The aim of the present study is to compare the two ADMs in terms of clinical and histological results in the setting of dermato-oncological surgery. Methods: Ten consecutive patients with medical indications to undergo surgical excision of skin cancers were treated with a 2-step procedure at our Dermatologic Surgery Unit. Immediately after tumor removal, both ADMs were positioned on the wound bed, one adjacent to the other. Closure through split-thickness skin grafting was performed after approximately 3 weeks. Conventional histology, immunostaining and ELISA assay were performed on cutaneous samples at different timepoints. Results: No significant differences were detected in terms of either final clinical outcomes or in extracellular matrix content of the neoformed dermis. However, Matriderm was observed to induce scar retraction more frequently. In contrast, Integra was shown to carry higher infectious risk and to be more slowly reabsorbed into the wound bed. Sometimes foreign body-like granulomatous reactions were also observed, especially in Integra samples. Conclusions: Even in the presence of subtle differences between the ADMs, comparable global outcomes were demonstrated after dermato-oncological surgery

The Italian Programma Alba for organ donation after circulatory death

A donation after cardiac Aims & ScopeCurrent A donation after cardiac/circulatory death (DCD), i.e. non-heart-beating donation (NHBD) programme named "Programma Alba" (Sunrise Programme) started in Pavia (Italy) in 2007. As in many countries, the main aim was to shorten the organ transplantation waiting lists. Initial targets were kidney and liver donations. Compared to other European countries and the US, the Italian DCD programme has taken more time to get established. Several reasons have apparently discouraged Italian physicians to set up such a transplantation programme, as unawareness of DCD organ viability, risk of diversion from heart beating donor programmes, ethical issues and the need to regulate medical requirements according to Italian legislation. Determination of death after irreversible cardiac arrest requires a 20-minute flat electrocardiogram, according to the law. This no-touch period is much longer than that established in legislations worldwide and organ viability after such a long no-touch period has been a major concern for many Italian transplant doctors over the years. Recent data allow up to 40-minutes warm ischemia time for preservation of organ viability. This has encouraged us to establish a DCD programme in Italy as well. Currently, three patients are out of dialysis with DCD kidneys. This paper analyzes all issues of DCD in detail from death definition and ascertainment according to Italian legislation to financial, technical and human resources needed to begin and establish such a transplantation programme in an Italian hospital

Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study

Targeting Kirsten Rat Sarcoma (KRAS) has been deemed impossible for long time, but new drugs have recently demonstrated promising results. Evidence on the outcome of KRAS-mutant advanced-NSCLC treated with new standard regimens are still scarce. Thus, we aimed at assessing the incidence and clinical impact of KRAS mutations in a real-life population of advanced-NSCLC, exploring the prognostic significance of distinct alterations

Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring <i>BRAF</i> Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups

Introduction: BRAF mutation involved 2–4% of lung adenocarcinoma. Differences in clinicopathologic features and patient outcome exist between V600E and non-V600E BRAF mutated NSCLC. Thus, we sought to assess the frequency and clinical relevance of BRAF mutations in a real-life population of advanced-NSCLC, investigating the potential prognostic significance of distinct genetic alterations. Materials and Methods: The present multicenter Italian retrospective study involved advanced BRAF mutant NSCLC. Complete clinicopathologic data were evaluated for BRAF V600E and non-V600E patients. Results: A total of 44 BRAFmut NSCLC patients were included (V600E, n = 23; non-V600E, n = 21). No significant differences in survival outcome and treatment response were documented, according to V600E vs. non-V600E mutations, although a trend towards prolonged PFS was observed in the V600E subgroup (median PFS = 11.3 vs. 6.0 months in non-V600E). In the overall population, ECOG PS and age significantly impacted on OS, while bone lesions were associated with shorter PFS. Compared to immunotherapy, first-line chemotherapy was associated with longer OS in the overall population, and especially in the BRAF V600E subtype. Conclusions: Here, we report on real-life data from a retrospective cohort of advanced-NSCLC harboring BRAF alterations. Our study offers relevant clues on survival outcome, therapeutic response, and clinicopathologic correlations of BRAF-mutant NSCLC